Market research
GBIO Generation Bio Co
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 36M
- P/E ratio
- Not available
- Analyst target
- 5.25
- Dividend yield
- Not available
- Beta
- 2.01
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US37148K1007
- Market cap
- 36M
- P/E ratio
- Not available
- Analyst target
- 5.25
- Dividend yield
- Not available
- Beta
- 2.01
About
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GBIO discussion.
5 years, 4 months ago
Generation Bio Co is currently in a long term downtrend where the price is trading 18.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Generation Bio Co gets an overall score of 1/5.